v3.26.1
Collaborations - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
May 31, 2021
Mar. 31, 2019
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Collaboration revenue     $ 5,000 $ 1,804,000 $ 31,000 $ 3,026,000  
Toray Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Variable consideration related to reimbursements for research and development services   $ 2,100,000          
Contract liabilities     815,000   815,000   $ 820,000
Contract liability, current     300,000   300,000   300,000
Contract liability, non-current     500,000   500,000   500,000
Revenue     5,000 200,000 18,000 200,000  
Toray Agreement | Prepaid Expenses and Other Current Assets              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Research and development services receivables     13,000   13,000   45,000
Genmab Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Allocated from stock purchase agreement $ 1,400,000            
Variable consideration related to reimbursements for research and development services 12,400,000            
Contract liabilities     1,175,000   1,175,000   1,173,000
Contract liability, current     500,000   500,000   100,000
Contract liability, non-current     700,000   700,000   1,100,000
Upfront payment received 10,000,000            
Potential future sale milestone payments $ 160,000,000            
Collaboration revenue     0 $ 1,600,000 13,000,000,000 $ 2,900,000  
Genmab Agreement | Prepaid Expenses and Other Current Assets              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Research and development services receivables     $ 0   $ 0   $ 600,000
Genmab Agreement | Common Stock              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Common stock sold 41,052            
Consideration in excess of fair value $ 1,400,000            
Purchase price under Stock Purchase Agreement 15,000,000            
Genmab Agreement | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Potential future sale milestone payments $ 125,000,000            
Series T Convertible Preferred Stock | Toray Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Common stock sold   35,875          
Consideration in excess of fair value   $ 1,500,000          
Allocated from stock purchase agreement   $ 1,500,000